New 'Living Drug' trial offers hope for Tough-to-Treat blood cancer
NCT ID NCT07370064
Summary
This study is testing a new, experimental treatment for adults whose acute myeloid leukemia (AML) has come back or hasn't responded to standard therapies. Doctors will collect a patient's own immune cells, modify them in a lab to better target the cancer, and then infuse them back. The main goals are to see if this personalized therapy is safe and if it can put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital oh Xuzhou Medical University
Xuzhou, Jiangsu, 221006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.